PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2264708

[Phosphodiesterase inhibitors].

A Sarkis·M Pornin
View original source ↗Export metadata ↓

Abstract

Phosphodiesterase III inhibitors constitute a new therapeutic group for congestive cardiac failure. They inhibit the degradation of cyclic adenosine monophosphate and increase the intracellular calcium. They have a double inotropic and vasodilator haemodynamics occurs without any increase in the myocardial effect. The improvement in the consumption of oxygen. The beneficial haemodynamic effect seems to last over a medium period of time, but the survival in the long term treatment is not yet known.

Explore related subjects

ElectrophysiologyHeart FailureHumansKidneyOxygen ConsumptionPhosphodiesterase InhibitorsEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Sarkis, M Pornin. 1990. [Phosphodiesterase inhibitors].. https://pubmed.ncbi.nlm.nih.gov/2264708/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

[Diagnostic approach].

Multiple mononeuropathies and peripheral polyneuropathies are due to a large variety of causes, and they frequently raise difficult diagnostic problems. Clinical examination has lost nothing of its value, but electrophysiological techniques and, in some cases, neuromuscular biopsy provide a better approach to the diagnosis of peripheral neuropathies. These neuropathies can now be classified according to their acute, subacute or chronic course and to the axonal or demyelinating nature of the physiopathological process involved.

Electrophysiology↗
PubMed1992

A soluble mitochondrial protein increases the voltage dependence of the mitochondrial channel, VDAC.

A soluble protein isolated from mitochondria has been found to modulate the voltage-dependent properties of the mitochondrial outer membrane channel, VDAC. This protein, called the VDAC modulator, was first found in Neurospora crassa and then discovered in species from other eukaryotic kingdoms. The modulator-containing fraction (at a crude protein concentration of 20 micrograms/ml) increases the voltage dependence of VDAC channels over 2-3-fold. At higher protein concentrations (50-100 micrograms/ml), some channels seem to remain in a closed state or be blocked while others display the higher voltage dependence and are able to close at low membrane potentials. By increasing the steepness of the voltage-dependent properties of VDAC channels, this modulator may serve as an amplifier in vivo to increase the sensitivity of the channels in response to changes in the cell's microenvironment, and consequently, regulate the metabolic flux across the outer mitochondrial membrane by controlling the gating of VDAC channels.

Electrophysiology↗